Results 41 to 50 of about 24,614 (195)

Treatment Strategies for Refractory Diabetic Macular Edema: Switching Anti-VEGF Treatments, adopting corticosteroid-based treatments, and combination therapy [PDF]

, 2016
Introduction: The pathophysiology of diabetic macular edema (DME) is complex, involving vascular endothelial growth factor (VEGF) and other inflammatory mediators.
Ciulla, Thomas A., Hussain, Rehan M.
core   +1 more source

Ranibizumab [PDF]

Reactions Weekly, 2020
  +7 more sources

Efficacy, Safety and Immunogenicity of Sun’s Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study

Ophthalmology and Therapy
Introduction The study aimed to evaluate comparability in terms of efficacy, safety and immunogenicity of Sun’s ranibizumab biosimilar with reference ranibizumab in patients with neovascular age-related macular degeneration (nAMD).
Asim K. Ghosh, Usha S. Nikumbh, Chaitanya K. Shukla, Rohit S. Laul, Abhishek Dixit, Santosh K. Mahapatra, Sameera Nayak, Urmil M. Shah, Sandeep Parwal, Narendran Venkatapathy, Natasha Radhakrishnan, Anup Kelgaonkar, Sandeep Saxena, Divyansh Mishra, Vivek Pravin Dave, Perwez Khan, Manojkumar R. Saswade, Malli S. Shantilal, Kim Ramasamy, Smitha Sreekanta, Mandodari Rajurkar, Maulik Doshi, Sapan Behera, Piyush Patel, Shilpi Dhawan, Lalit Lakhwani   +25 more
doaj   +1 more source

The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review [PDF]

, 2017
The acute and chronic effects of repeated intravitreal antivascular endothelial growth factor (VEGF) injections on intraocular pressure have not been fully characterized, and the development of sustained ocular hypertension could adversely affect ...
Bracha, Peter, Cantor, Louis B., Ciulla, Thomas A., Moore, Nicholas A., WuDunn, Darrell   +4 more
core   +1 more source

Aptamer‐Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies

Advanced Healthcare Materials, EarlyView.
Aptamer‐based delivery systems targeting NGF and VEGF hold significant potential for precise and sustained treatment of complex diseases affecting both the anterior and posterior segments of the eye. This review critically summarizes current strategies for NGF and VEGF delivery as well as VEGF sequestration, providing a clinical perspective on how ...
Nadine Best, Gizem Karabiyik, Gerd Geerling, Sarah Barbara Zwingelberg, Gregor Lang, Martin Humenik   +5 more
wiley   +1 more source

Hosszú távú intravitrealis ranibizumabkezelés exsudativ időskori maculadegenerációban [PDF]

, 2013
Bevezetés: Az exsudativ időskori maculadegeneráció kezelésére alkalmazott intravitrealis ranibizumabinjekcióval szerzett eddigi tapasztalatok kedvezőek.
Borbándy, Ágnes, Kiss, Huba, Lukács Regina, Menkens Hanna, Németh, János Tibor, Papp, András, Resch, Miklós, Szabó, Antal   +7 more
core   +1 more source

Image analysis method for measurement and prediction of intra‐matrix IgG diffusion

Biotechnology Progress, EarlyView.
Experimental and image analysis workflow for b‐IgG diffusion in hyaluronic acid (HA) matrix. Abstract Measurement and imaging of intra‐matrix protein therapeutics diffusion is important due to the emergence of injectable biologics currently in various stages of research and clinical testing.
Riya Debbarma, Antonio C. F. dos Santos, Michael Ladisch   +2 more
wiley   +1 more source

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration

Cost Effectiveness and Resource Allocation, 2008
Background Intravitreal ranibizumab prevents vision loss and improves visual acuity in patients with neovascular age-related macular degeneration, but it is expensive, and efficacy beyond 2 years is uncertain.
Matthews Jane P, Hurley Susan F, Guymer Robyn H   +2 more
doaj   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

Clinical research progress on ranibizumab in the treatment of retinopathy of prematurity

Shanghai Jiaotong Daxue xuebao. Yixue ban
Retinopathy of prematurity (ROP) is a retinal vascular proliferative fundus disease that occurs in premature infants with low birth weight. Currently, a widely used treatment is intravitreal injection of anti-vascular endothelial growth factor (VEGF ...
Chen Zhijun, Peng Jie, Zhang Xuerui, Zhao Peiquan   +3 more
doaj   +1 more source